Gapping up
In reaction to earnings/guidance:
- BMBL +9.7%, JD +6.3%, AMC +6.1%, ASAN +5.9%, GOGO +5.8%, SKLZ +4.9%, FNV +4.4%, KRO +4.4%, FSM +3.3%, BLDP +3.2%, GCO +3.2%, KYMR +2.9%, DCBO +2.8%, DGX +1.7%, GDS +1.1%
Other news:
- VIR +61.9% (Vir Biotechnology and GSK reports VIR-7831 reduces hospitalization and risk of death in early treatment of adults with COVID-19)
- OGI +41.5% (OrganiGram and BAT form product development collaboration -- includes strategic investment from BAT for 19.9% equity interest)
- SPPI +27.4% (announces that the U.S. Food and Drug Administration has granted Fast Track designation for poziotinib for the treatment of non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations)
- AVEO +22.8% (continued momentum after receiving FDA approval for FOTIVDA)
- SLGG +15.5% (announces the acquisition of Mobcrush)
- GOEV +7.7% (introduces fully-electric pickup truck )
- ALKS +6.8% (FDA grants orphan drug designation to nemvaleukin alfa (nemvaleukin, formerly referred to as ALKS 4230), for the treatment of mucosal melanoma)
- BTAI +6.3% (submits NDA to FDA for BXCL501; also reported earnings)
- MSGN +5.6% (weighing merger with MSG Entertainment [MSGE], per Bloomberg)
- SPFR +4.3% (following report that co is weighing merger with Velo3D)
- AXON +4.2% (Axon and drone manufacturer Skydio announce strategic partnership for law enforcement and emergency responders)
- PLTR +4% (Palantir Technologies and Faurecia (FURCF) announce six-year partnership)
- VCVC +3.9% (REE Automotive files Registration Statement on Form F-4 in connection with its proposed business combination with 10x Capital Venture Acquisition Corp)
- SCOR +3.6% (announced an agreement to provide Ovation with Comscore's video-on-demand audience measurement)
- BAND +3.2% (convertible senior notes offering)
- ENFA +2.9% (in talks for merger with BuzzFeed, according to Bloomberg)
- NUVB +2.9% (FDA grants orphan drug designation to NUV-422 for the treatment of patients with malignant gliomas)
- CRIS +2.5% (announced abstract for CA-4948 accepted for presentation at AACR Annual Meeting)
- SURF +2.5% (announced presentations at AACR Annual Meeting)
- BNTX +2.2% (Pfizer and BioNTech (BNTX) confirm 97% vaccine effectiveness; data suggests PFE/BNTX vaccine is 94% effective against asymptomatic SARS-CoV-2 infections) RIGL +1.8% (completed patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib for the treatment of hospitalized COVID-19 patients)
- FI +1.6% (Frank's International and Expro to combine to create a leading full-cycle service provider)
- RWT +1.4% (increased dividend)
Analyst comments:
- CATB +17.2% (upgraded to Outperform from Perform at Oppenheimer)
- ADT +4.8% (upgraded to Buy from Hold at Deutsche Bank)
- MELI +4.4% (upgraded to Buy from Neutral at BTIG Research)
- AER +4.3% (upgraded to Overweight from Equal-Weight at Stephens)
- CWH +4.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- QRVO +3.8% (upgraded to Overweight from Equal Weight at Barclays)
- DHI +2.3% (upgraded to Overweight from Neutral at JP Morgan)
- APA +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- COST +1.5% (upgraded to Overweight from Equal Weight at Wells Fargo)
- OXY +1.5% (upgraded to Peer Perform from Underperform at Wolfe Research)